Sandhu H S, Kanim L E, Toth J M, Kabo J M, Liu D, Delamarter R B, Dawson E G
Department of Orthopaedic Surgery, UCLA School of Medicine, USA.
Spine (Phila Pa 1976). 1997 Jun 1;22(11):1171-80. doi: 10.1097/00007632-199706010-00001.
L4-L5 intertransverse process fusions were produced with 58 micrograms, 230 micrograms, or 920 micrograms of recombinant human bone morphogenetic protein-2 in 20 dogs. Eleven had traditional decortication of posterior elements before insertion of the implant. Nine were left undecorticated. All animals were evaluated 3 months after surgery.
To determine whether decortication is a prerequisite for successful fusion in the presence of osteoinductive proteins such as bone morphogenetic protein-2.
Recombinant osteoinductive proteins can induce de novo bone in ectopic soft-tissue sites in the absence of bone marrow elements. Traditional methods for achieving spinal fusion rely on exposure of bone marrow through decortication to facilitate osteogenesis. It is hypothesized that the presence of an implanted osteoinductive protein obviates the need for exposure and release of host inductive factors.
Recombinant human bone morphogenetic protein-2-induced intertransverse process fusions were performed with and without decortication. Fusion sites were evaluated by computed tomography imaging, high-resolution radiography, manual testing, mechanical testing, and histologic analysis.
One hundred percent of decorticated spines and 89% of undecorticated spines were clinically fused by 3 months. Ninety-one percent of decorticated spines and 78% of undecorticated specimens exhibited bilateral transverse process osseous bridging. The only spines that failed to achieve solid bilateral arthrodesis were in the lowest dose group. With the higher two doses, there was histologic evidence of osseous continuity between the fusion mass and undecorticated transverse processes.
There were no statistical differences in clinical and radiographic fusion rates between decorticated and undecorticated sites. With higher doses of recombinant human bone morphoganetic protein-2, there was little histologic distinction between fusions in decorticated versus undecorticated spines.
对20只犬进行L4-L5横突间融合,分别植入58微克、230微克或920微克重组人骨形态发生蛋白-2。11只在植入物插入前对后部结构进行了传统的去皮质处理。9只未进行去皮质处理。所有动物在术后3个月进行评估。
确定在存在骨形态发生蛋白-2等骨诱导蛋白的情况下,去皮质是否是成功融合的先决条件。
重组骨诱导蛋白可在无骨髓成分的异位软组织部位诱导新生骨形成。实现脊柱融合的传统方法依赖于通过去皮质暴露骨髓以促进骨生成。据推测,植入的骨诱导蛋白的存在消除了暴露和释放宿主诱导因子的必要性。
进行有或无去皮质处理的重组人骨形态发生蛋白-2诱导的横突间融合。通过计算机断层扫描成像、高分辨率放射摄影、手动测试、力学测试和组织学分析对融合部位进行评估。
到3个月时,100%进行去皮质处理的脊柱和89%未进行去皮质处理的脊柱实现了临床融合。91%进行去皮质处理的脊柱和78%未进行去皮质处理的标本出现双侧横突骨桥形成。唯一未实现牢固双侧关节融合的脊柱在最低剂量组。使用较高的两个剂量时,有组织学证据表明融合块与未进行去皮质处理的横突之间存在骨连续性。
进行去皮质处理和未进行去皮质处理的部位在临床和影像学融合率上无统计学差异。使用较高剂量的重组人骨形态发生蛋白-2时,进行去皮质处理与未进行去皮质处理的脊柱融合在组织学上几乎没有区别。